Choline PET/CT for imaging prostate cancer: an update

Whole-body positron emission tomography/computed tomography (PET/CT) with [ 11 C]- and [ 18 F]-labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. 11 C- and 18 F-choline PET/CT are used successfully for restaging prostate cancer in p...

Full description

Saved in:
Bibliographic Details
Published in:Annals of nuclear medicine 2013-08, Vol.27 (7), p.581-591
Main Authors: Kitajima, Kazuhiro, Murphy, Robert C., Nathan, Mark A.
Format: Article
Language:English
Subjects:
Choline
Humans
Imaging
Male
Medicine
Medicine & Public Health
Multimodal Imaging - methods
Nuclear Medicine
Positron-Emission Tomography - methods
Prostatic Neoplasms - diagnostic imaging
Prostatic Neoplasms - pathology
Radiology
Recurrence
Review Article
Tomography, X-Ray Computed - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Whole-body positron emission tomography/computed tomography (PET/CT) with [ 11 C]- and [ 18 F]-labeled choline derivates has emerged as a promising molecular imaging modality for the evaluation of prostate cancer. 11 C- and 18 F-choline PET/CT are used successfully for restaging prostate cancer in patients with biochemical recurrence of disease after definitive therapy, especially when the serum prostate-specific antigen level is >1.0 ng/mL. 11 C- and 18 F-choline PET/CT have more limited roles for the initial staging of prostate cancer and for the detection of tiny lymph node metastases due to the low spatial resolution inherent to PET. Overall, these modalities are most useful in patients with a high pre-test suspicion of metastatic disease. The following is a review of the current clinical roles of 11 C- and 18 F-choline PET/CT in the management of prostate cancer.
ISSN:0914-7187
1864-6433
DOI:10.1007/s12149-013-0731-7